AI Article Synopsis
- The study examines the effectiveness of intravitreal bevacizumab as either a main or additional treatment for severe retinopathy of prematurity in infants.
- Nine infants with severe cases were analyzed; they had varying levels of gestational age and birth weight, and required treatment due to progression despite laser therapies.
- Results showed that bevacizumab successfully reduced active blood vessel growth in all treated eyes, with favorable anatomical outcomes and no significant complications reported.
Article Abstract
Purpose: To investigate the benefit of intravitreal bevacizumab as supplemental or primary treatment for retinopathy of prematurity.
Methods: The files of nine consecutive infants treated with intravitreal bevacizumab for bilateral severe posterior retinopathy of prematurity were reviewed.
Results: Gestational age was 24 weeks to 27 weeks, and birth weight was 660 g to 1,131 g. Indications for treatment were retinopathy of prematurity progression from Stage 3 to 4A or 2 to 3 with extraretinal neovascularization despite laser treatment; active neovascular Stage 4A disease after laser and cryo-treatment; anterior segment neovascularization and bleeding after laser treatment; and aggressive posterior disease with tunica vasculosa lentis and vitreous haze, which prevented laser treatment. One patient (two eyes) underwent lens-sparing vitrectomy after bevacizumab treatment; one eye acquired macular fold. One patient underwent bilateral scleral buckle. Bevacizumab treatment was associated with subsidence of the active vascular component in all eyes. Anatomical results were favorable in 17 eyes. There were no local or systemic complications.
Conclusion: Intravitreal bevacizumab may serve as a supplemental therapeutic agent for severe laser-refractory retinopathy of prematurity or as monotherapy when media opacities preclude diode laser photocoagulation or the patient is too sick for lengthy laser treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IAE.0b013e31820d4000 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Progressive anterior segment involvement of an infant with corneoscleral juvenile xanthogranuloma refractory to topical steroids.
Am J Ophthalmol Case Rep
December 2024
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Purpose: To report a case of corneoscleral juvenile xanthogranuloma (JXG) with progressive anterior segment involvement refractory to topical steroids.
Observations: A 4-month-old male was referred for a new-onset subconjunctival lesion in the right eye. He was found to have a thickened, yellow corneoscleral lesion and hyphema, presumed to be ocular JXG.
Focal choroidal excavation (FCE)-related choroidal neovascular membrane (CNV) in a child.
Retin Cases Brief Rep
June 2024
Department of Ophthalmology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
Purpose: To report the rare clinical, optical coherence tomography (OCT), and OCT-angiography findings of a visually significant choroidal neovascular membrane (CNV) in the setting of focal choroidal excavation (FCE) in a child.
Methods: Case report and literature review.
Results: A 9-year-old girl with FCE-related central CNV based on clinical findings and multimodal imaging.
Intravitreal melatonin for the prevention of radiation retinopathy: a step beyond bevacizumab.
Int J Radiat Biol
January 2025
Department of Radiation Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Purpose: Intravitreal bevacizumab has been utilized to mitigate radiation retinopathy, yet the potential role of intravitreal melatonin for its prevention remains unexplored. This study aims to evaluate and compare the efficacy of intravitreal melatonin and bevacizumab in preventing radiation retinopathy in an experimental animal model.
Materials And Methods: Twelve healthy male New Zealand white rabbits ( = 24 eyes) received a single 3000 cGy irradiation dose in both eyes.
Anterior Segment Optical Coherence Tomography Evaluation of a Dexamethasone Intravitreal Implant in the Crystalline Lens: A Case Report.
Int Med Case Rep J
January 2025
Department of Ophthalmology, Centro Hospitalar Universitário de São João, Porto, Portugal.
Purpose: Ozurdex is a dexamethasone intravitreal implant approved for the treatment of macular edema secondary to branch or central retinal vein occlusion, non-infectious uveitis affecting the posterior segment of the eye, and diabetic macular edema.
Patients And Methods: We report a case of an accidental injection of the implant into the crystalline lens, successfully managed by surgery afterwards. The case description is supported by Anterior Segment Optical Coherence Tomography (AS-OCT) images.
The Effects of Anti-Vascular Endothelial Growth Factor Loading Injections on Retinal Microvasculature in Diabetic Macular Edema.
Transl Vis Sci Technol
December 2024
Department of Ophthalmology, Kyung Hee University Medical Center, Kyung Hee University, Seoul, Korea.
Purpose: To evaluate changes in the retinal microvasculature using widefield swept-source optical coherence tomography angiography (SS-OCTA) following three anti-vascular endothelial growth factor (anti-VEGF) loading injections for diabetic macular edema (DME).
Methods: Thirty-four treatment-naïve patients with DME received an initial three loading injections, followed by injections on an as-needed basis. Macular ischemia was evaluated based on the foveal avascular zone (FAZ) area, perfusion density, and vessel density on a 3 × 3-mm SS-OCTA image.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!